Low-pro­file RNAi play­er lands on HKEX fol­low­ing mod­est $50M IPO

A low-pro­file small in­ter­fer­ing RNA play­er has man­aged to squeeze in its IPO be­fore the year ends, adding an­oth­er list­ing to the Hong Kong stock ex­change’s tal­ly.

Sir­naomics is mak­ing its HKEX de­but with a mod­est raise of slight­ly over $50 mil­lion, with the po­ten­tial of adding about $10 mil­lion if the over-al­lot­ment op­tion is ex­er­cised in full.

CEO Patrick Lu found­ed the biotech all the way back in 2007, set­ting up an ear­ly dis­cov­ery op­er­a­tion in Gaithers­burg, MD af­ter a tran­si­tion from re­search at George­town in­to in­dus­try — first work­ing for No­var­tis then co-found­ing an­oth­er com­pa­ny called In­tr­a­digm. Through it all, he was fo­cused on what he calls nu­cle­ic acid drug de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER